High-purity therapeutic and active research APIs synthesized under strict ISO/cGMP quality management parameters at multi-ton batch volumes.
An authoritative engineering assessment of Melanotan II (Mt 2) synthesis, structure-activity relationship (SAR), chemical stability, and downstream commercial scale-up.
Melanotan II (CAS NO: 121062-08-6) is a synthetic, cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). The chemical sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 utilizes an internal lactam bridge engineered between the aspartic acid and lysine side chains. This covalent cyclization imposes rigid conformational constraints, drastically enhancing enzymatic resistance compared to linear melanocortin peptides.
Through precise D-Phe substitution at position 7 and side-chain macrocyclization, Mt 2 achieves high nanomolar binding affinity across human melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R. In industrial analytical batches, the preservation of the stereochemical integrity of D-Phenylalanine is critical; any racemization during automated solid-phase assembly causes marked loss of biological binding and yields unwanted epimer impurities.
Leading B2B pharmaceutical buyers require comprehensive chromatographic transparency. Major impurity risks in commercial Mt 2 manufacturing stem from beta-alanine deletion sequences, incomplete lactam ring closure (linear precursors), and high residual trifluoroacetic acid (TFA). Thinheal implements orthogonal prep-HPLC purifications achieving purity thresholds strictly ≥99.0% with total individual unknowns ≤0.5%.
How Hangzhou Thinheal Pharma-Tech leverages vertically integrated peptide synthesis infrastructure to guarantee stable pricing and uncompromised regulatory compliance.
China commands over 75% of global fine-chemical amino acid precursor production. We synthesize custom Fmoc-protected amino acids, coupling agents (HBTU, HATU, DIC), and specialized CTC resins in-house, immunizing global buyers against upstream raw material volatility and delivery bottlenecks.
With modern glass-lined and stainless peptide reactors scaling from 50L to 3000L, Thinheal supports batch consolidation that reduces analytical validation friction. Kilogram-to-ton campaigns execute with high atom efficiency, driving down manufacturing cost per gram while preserving batch-to-batch uniformity.
Our manufacturing protocols mirror stringent ICH Q7 API standards. High-resolution RP-HPLC, LC-MS/MS, Ion Chromatography for acetate/chloride/trifluoroacetate monitoring, and automated TOC analysis are employed to release lot-specific documentation that fulfills Western and Asian audit mandates.
Sourcing risks disappear when logistics are managed by seasoned professionals. Thinheal operates four direct global export desks providing real-time compliance communication across Europe, the Americas, CIS countries, the Middle East, and the Asia-Pacific with robust cold-chain supply operations.
Clear, auditable price break architectures tailored for biopharmaceutical research entities, clinical formulation developers, and authorized institutional distributors.
| Order Tier (Gross Quantity) | Target Purity (HPLC) | Salt / Counter-Ion Form | Indicative Price Range (USD/g) | Lead Time & Regulatory Package |
|---|---|---|---|---|
| Pilot / Evaluation Tier (10g – 100g) | ≥98.5% | Lyophilized TFA or Acetate | $18.00 – $26.00 | Immediate Stock HPLC, MS, standard Certificate of Analysis |
| Pre-Clinical / Batch Tier (500g – 2,000g) | ≥99.0% | Acetate Salt (Pharmaceutical) | $9.50 – $14.50 | 5 - 7 Workdays Full CoA, Endotoxin, Water Content (Karl Fischer) |
| Commercial Pilot Scale (5kg – 20kg) | ≥99.2% | Controlled Acetate (≤12%) | $5.80 – $8.20 | 10 - 14 Workdays Batch Production Records, Impurity Dossier, Heavy Metals |
| Industrial Multi-Ton Campaign (≥50kg) | ≥99.5% | Customized Target Ion | Contract Negotiated | Custom CDMO Site Audit, Open-file DMF Support, Stability Data |
* Note: Final pricing varies based on counter-ion conversion requirements (TFA to Acetate), lyophilization vial formatting, and localized import tariff schedules.
Navigating the cross-border compliance landscape: how global life science firms integrate Mt 2 safely within authorized pre-clinical and investigative frameworks.
Melanotan II is regulated across international jurisdictions primarily as an Active Pharmaceutical Ingredient (API) intended for Research Use Only (RUO) or investigational clinical development. Thinheal ensures every shipment includes exhaustive chemical categorization (HS Code: 2937.19.0090), Safety Data Sheets (SDS per GHS standards), and detailed declaration of purity to streamline clearance across North American and European customs ports.
In specialized academic research and dermatology laboratories, Mt 2 serves as a pivotal tool compound for probing melanogenesis kinetics and UV photoprotective cell pathways. Pre-clinical models leverage its activation of MC1R on melanocytes to evaluate eumelanin synthesis vs. pheomelanin ratios, DNA damage repair mechanisms, and reactive oxygen species (ROS) neutralization under ultraviolet stress conditions.
Due to central nervous system penetration and MC3R/MC4R agonism, Mt 2 continues to be deployed across neuroendocrine and behavioral investigation. Pre-clinical neuropharmacology studies examine its direct stimulation of the paraventricular nucleus in hypothalamic pathways, modulating appetite suppression models, insulin homeostasis, and central sexual function mediation (precursor biology to Bremelanotide PT-141).
Future-proofing peptide therapeutics: the transition toward eco-friendly coupling reagents, continuous-flow synthesis, and automated impurity suppression.
Traditional peptide manufacturing consumes massive volumes of N,N-dimethylformamide (DMF) and dichloromethane (DCM). Thinheal is pioneering green peptide chemistry across its Hangzhou plants, introducing bio-based alternative solvents such as 2-MeTHF and Cyrene™, coupled with continuous solvent reclamation units that cut chemical waste footprints by up to 60%.
The integration of inline UV-vis spectrometers, real-time process conductivity monitors, and AI-driven predictive peptide synthesis models ensures immediate detection of deprotection stalling or coupling incompleteness. This automated closed-loop synthesis prevents aggregation cascades common to challenging cyclic peptides like Mt 2.
While Solid-Phase Peptide Synthesis (SPPS) remains supreme for milligram to kilogram production, ultra-large commercial contracts leverage Liquid-Phase Peptide Synthesis (LPPS) or chemo-enzymatic segment condensation. Thinheal's R&D team implements hybrid fragment-coupling approaches to shatter output caps for long and cyclic sequences.
Direct, transparent answers regarding manufacturing qualifications, batch release dossiers, storage stability, and international supply coordination.
Discover our comprehensive range of specialized peptide APIs, dual agonists, and cosmetic compounds produced under advanced chromatographic purification standards.
Thin